Estadístiques de Novel oral mTORC1/2 inhibitor TAK-228 has synergistic antitumor effects when combined with paclitaxel or PI3Kα inhibitor TAK-117 in preclinical bladder cancer models
Visites totals
views | |
---|---|
Novel oral mTORC1/2 inhibitor TAK-228 has synergistic antitumor effects when combined with paclitaxel or PI3Kα inhibitor TAK-117 in preclinical bladder cancer models | 143 |
Visites totals per mes
views | |
---|---|
August 2024 | 4 |
September 2024 | 3 |
October 2024 | 0 |
November 2024 | 2 |
December 2024 | 0 |
January 2025 | 0 |
February 2025 | 0 |
Visites al fitxer
views | |
---|---|
hernandez-mcr-nove.pdf(legacy) | 147 |
hernandez-mcr-nove.pdf | 20 |
Vistes principals per país
views | |
---|---|
United States | 79 |
Spain | 19 |
Sweden | 13 |
China | 9 |
Ireland | 6 |
Germany | 4 |
South Korea | 2 |
Belgium | 1 |
Czechia | 1 |
Iran | 1 |
Italy | 1 |
Mexico | 1 |
Malaysia | 1 |
Netherlands | 1 |
Romania | 1 |
Russia | 1 |
Visites principals per ciutat
views | |
---|---|
San Ramon | 22 |
Fairfield | 11 |
Mountain View | 9 |
Shenzhen | 8 |
Barcelona | 7 |
Cambridge | 5 |
Dublin | 5 |
Ashburn | 4 |
Menlo Park | 3 |
Málaga | 3 |
San Diego | 3 |
Amorebieta | 2 |
Boardman | 2 |
Daejeon | 2 |
Ann Arbor | 1 |
Bucharest | 1 |
Catania | 1 |
Cupertino | 1 |
Madrid | 1 |
Mérida | 1 |
Olesa De Montserrat | 1 |
Premiá De Mar | 1 |
Redwood City | 1 |
Seattle | 1 |
Shah Alam | 1 |
Vitoria | 1 |